Division of Hematology and Hematological Malignancies, Department of Medicine, University of Calgary, Alberta, Canada.
Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
Thromb Res. 2021 Jun;202:134-138. doi: 10.1016/j.thromres.2021.03.012. Epub 2021 Mar 25.
Exogenous hormone therapies, such as combined oral contraceptives (COC) and hormone replacement therapy (HRT), cause blood hypercoagulability and are a risk factor for venous thromboembolism (VTE). There is controversy on how strong this "provoking" risk factor is, and how other risk factors may synergise VTE risk. We aim to review the latest literature on the risk of initial and recurrent VTE with COC and HRT use to provide guidance for decision-making about duration of anticoagulation, and guide future research efforts.
外源性激素治疗，如复方口服避孕药（COC）和激素替代疗法（HRT），可导致血液高凝状态，是静脉血栓栓塞症（VTE）的一个危险因素。关于这种“诱发”危险因素的强度以及其他危险因素如何协同增加 VTE 风险存在争议。我们旨在回顾有关 COC 和 HRT 使用与初次和复发性 VTE 风险的最新文献，为抗凝时间的决策提供指导，并指导未来的研究工作。
